Does Oxcarbazepine Warrant Therapeutic Drug Monitoring?
- 1 January 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 47 (12), 767-778
- https://doi.org/10.2165/0003088-200847120-00002
Abstract
Oxcarbazepine, the 10-keto analogue of carbamazepine, is approved for the treatment of partial seizures or generalized tonic-clonic seizures. The primary metabolite of oxcarbazepine is monohydroxylated derivative (MHD). This review follows a decision-making algorithm to determine if therapeutic drug monitoring of MHD is warranted.Important factors to take into account include the appropriateness of oxcarbazepine for the therapeutic indication; ability to measure MHD concentrations; existence of a good concentration-response relationship, narrow therapeutic range or unpredictable pharmacokinetic parameters; assessability of the pharmacological response of oxcarbazepine; adequate duration of therapy; and potential influence of MHD concentrations in the clinical decision-making process. Based on the available evidence, therapeutic drug monitoring of MHD is not routinely warranted but may be beneficial in optimizing seizure control at the extremes of age, during pregnancy, in renal insufficiency, or to determine the significance of potential drug interactions or rule out noncompliance.Keywords
This publication has 59 references indexed in Scilit:
- Pharmacokinetics and Therapeutic Drug Monitoring of Newer Antiepileptic Drugs During Pregnancy and the PuerperiumClinical Pharmacokinetics, 2007
- Adult epilepsyThe Lancet, 2006
- Pharmacokinetic Variability of Newer Antiepileptic DrugsClinical Pharmacokinetics, 2006
- Clinical Pharmacokinetics of New-Generation Antiepileptic Drugs at the Extremes of AgeClinical Pharmacokinetics, 2006
- Simultaneous analysis of six antiepileptic drugs and two selected metabolites in human plasma by liquid chromatography after solid-phase extractionAnalytica Chimica Acta, 2002
- EpilepsyThe New England Journal of Medicine, 2001
- Newer AnticonvulsantsDrugs, 2000
- Is There a Role for Therapeutic Drug Monitoring of New Anticonvulsants?Clinical Pharmacokinetics, 2000
- Clinical Pharmacokinetics in the 21st CenturyClinical Pharmacokinetics, 1998
- The pharmacokinetics of oxcarbazepine and its active metabolite 10‐hydroxy‐carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acidBritish Journal of Clinical Pharmacology, 1993